Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 9/20 | 0.64 |
| ▸ | GABRD | O14764 | 9/20 | 0.64 |
| ▸ | GABRA1 | P14867 | 9/20 | 0.64 |
| ▸ | GABRB1 | P18505 | 9/20 | 0.64 |
| ▸ | GABRG2 | P18507 | 9/20 | 0.64 |
| ▸ | GABRB3 | P28472 | 9/20 | 0.64 |
| ▸ | GABRA5 | P31644 | 9/20 | 0.64 |
| ▸ | GABRA3 | P34903 | 9/20 | 0.64 |
| ▸ | GABRA2 | P47869 | 9/20 | 0.64 |
| ▸ | GABRB2 | P47870 | 9/20 | 0.64 |
| ▸ | GABRA4 | P48169 | 9/20 | 0.64 |
| ▸ | GABRE | P78334 | 9/20 | 0.64 |
| ▸ | GABRA6 | Q16445 | 9/20 | 0.64 |
| ▸ | GABRG1 | Q8N1C3 | 9/20 | 0.64 |
| ▸ | GABRG3 | Q99928 | 9/20 | 0.64 |
| ▸ | GABRQ | Q9UN88 | 9/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | IDO1 | P14902 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | AHR | P35869 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13100678 | 0.85 | KIF11 (0.56) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL12938276 | 0.81 | GABRP (0.68) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL13182625 | 0.79 | KIF11 (0.44) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL14689472 | 0.79 | CHUK (0.58) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL10642293 | 0.78 | GABRP (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1982871 | 0.78 | GABRP (0.64) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL10644440 | 0.78 | GABRP (0.64) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6446989 | 0.78 | GABRP (0.64) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1984445 | 0.78 | GABRP (0.64) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL28643704 | 0.78 | GABRP (0.64) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334299-B2 | β-carboline for the treatment of neurodegenerative diseases | ELLNEUROXX, LTD. (DE) | 2012-12-18 | — | — | US | claimed |
| US-20100143474-A1 | B-CARBOLINE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ELLNEUROXX, LTD. | 2010-06-10 | — | — | US | claimed |
| EP-0054507-B1 | 3-SUBSTITUTED BETA-CARBOLINES, PROCESS FOR THEIR PRODUCTION AND COMPOSITIONS CONTAINING THEM | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-02-17 | — | — | EP | claimed |
| US-20240132494-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2024-04-25 | — | — | US | disclosed |
| US-11866427-B2 | Kinase inhibitor compounds and compositions and methods of use | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2024-01-09 | — | — | US | disclosed |
| US-20210094950-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH | 2021-04-01 | — | — | US | disclosed |
| EP-3768267-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | Icahn School of Medicine at Mount Sinai (US) | 2021-01-27 | — | — | EP | disclosed |
| WO-2019183245-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-09-26 | — | — | WO | disclosed |
| EP-3122750-B1 | BICYCLIC COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-09-04 | — | — | EP | disclosed |
| EP-2900669-B1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AND RELATED COMPOUNDS AS AUTOTAXIN (ATX) INHIBITORS AND AS INHIBITORS OF THE LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION FOR TREATING E.G. RENAL DISEASES | HOFFMANN LA ROCHE (CH) | 2019-09-04 | — | — | EP | disclosed |
| WO-2015144605-A1 | BICYCLIC COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-10-01 | — | — | WO | disclosed |
| US-8551956-B2 | Compositions containing peptides with non-natural amino acids and methods of use | AVON PRODUCTS, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-8551956-B2 | Compositions containing peptides with non-natural amino acids and methods of use | AVON PRODUCTS, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20090082252-A1 | Compositions Containing Peptides with Non-Natural Amino Acids and Methods of Use | AVON PRODUCTS INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082252-A1 | Compositions Containing Peptides with Non-Natural Amino Acids and Methods of Use | AVON PRODUCTS INC. | 2009-03-26 | — | — | US | disclosed |
| WO-2007100874-A2 | COMPOSITIONS CONTAINING PEPTIDES WITH NON-NATURAL AMINO ACIDS AND METHODS OF USE | AVON PRODUCTS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| US-4731358-A | β-carbolines and their use as tranquilizers | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132494-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | CSNK1A1, DYRK1A, CSNK1G3 | GABRP 1344/4885GABRD 1065/4885GABRA1 1030/4885 |
| US-20100143474-A1 | B-CARBOLINE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PARK7, SNCA, CHAT | GABRP 1512/4885GABRD 2383/4885GABRA1 803/4885 |
| US-11866427-B2 | Kinase inhibitor compounds and compositions and methods of use | CSNK1A1, CSNK1E, CSNK1G3 | GABRP 1113/4885GABRD 974/4885GABRA1 940/4885 |
| US-20210094950-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | CSNK1A1, CSNK1E, CSNK1G3 | GABRP 1113/4885GABRD 974/4885GABRA1 940/4885 |
| US-20090082252-A1 | Compositions Containing Peptides with Non-Natural Amino Acids and Methods of Use | CUTA, NGLY1, LNPEP | GABRP 1492/4885GABRD 2942/4885GABRA1 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.